| Characteristic . | Total (N = 399) . |
|---|---|
| Median age (range); years | 62 (22–83) |
| Sex; n (%) | |
| Male | 228 (57.1) |
| Female | 171 (42.9) |
| Race; n (%) | |
| Caucasian | 380 (95.2) |
| Hispanic | 13 (3.3) |
| African | 6 (1.5) |
| ECOG-PS; n (%) | |
| Score 0 | 213 (53.4) |
| Score 1 | 125 (31.3) |
| Score ≥ 2 | 20 (5) |
| Unknown | 41 (10) |
| Tumor grade WHO; n (%)a | |
| Grade 1 | 147 (36.8) |
| Grade 2 | 197 (49.4) |
| Grade 3 | 50 (12.5) |
| Unknown | 5 (1.3) |
| Differentiation; n (%) | |
| NET | 361 (90.5) |
| NEC | 28 (7) |
| Unknown | 10 (2.5) |
| Functionality; n (%) | |
| Yes | 98 (24.6) |
| No | 295 (73.9) |
| Unknown | 6 (1.5) |
| Primary tumor location, n (%) | |
| Small intestine | 177 (44.4) |
| Pancreas | 167 (41.9) |
| Colorectal | 18 (4.5) |
| Gastric | 10 (2.5) |
| Other/unknown | 25 (6.3) |
| Metastasis at inclusion, n (%) | |
| 0 | 15 (3.8) |
| 1 | 227 (56.9) |
| ≥2 | 157 (39.3) |
| Most common sites of metastasis; n (%) | |
| Liver | 332 (83.2) |
| Lymph nodes | 86 (21.6) |
| Peritoneum | 55 (13.8) |
| Lung | 28 (7.0) |
| Previous lines; n (%) | |
| 1 | 217 (54.4) |
| 2 | 92 (23.1) |
| ≥2 | 90 (22.6) |
| Type of previous lines, n (%) | |
| SSA | 342 (85.7) |
| PRRT | 109 (27.3) |
| TKI | 108 (27.1) |
| Chemotherapy | 80 (20.1) |
| Clinical trial | 42 (10.5) |
| TACE or locoregional therapy | 11 (2.8) |
| Immunotherapy | 7 (1.8) |
| Others | 6 (1.5) |
| Characteristic . | Total (N = 399) . |
|---|---|
| Median age (range); years | 62 (22–83) |
| Sex; n (%) | |
| Male | 228 (57.1) |
| Female | 171 (42.9) |
| Race; n (%) | |
| Caucasian | 380 (95.2) |
| Hispanic | 13 (3.3) |
| African | 6 (1.5) |
| ECOG-PS; n (%) | |
| Score 0 | 213 (53.4) |
| Score 1 | 125 (31.3) |
| Score ≥ 2 | 20 (5) |
| Unknown | 41 (10) |
| Tumor grade WHO; n (%)a | |
| Grade 1 | 147 (36.8) |
| Grade 2 | 197 (49.4) |
| Grade 3 | 50 (12.5) |
| Unknown | 5 (1.3) |
| Differentiation; n (%) | |
| NET | 361 (90.5) |
| NEC | 28 (7) |
| Unknown | 10 (2.5) |
| Functionality; n (%) | |
| Yes | 98 (24.6) |
| No | 295 (73.9) |
| Unknown | 6 (1.5) |
| Primary tumor location, n (%) | |
| Small intestine | 177 (44.4) |
| Pancreas | 167 (41.9) |
| Colorectal | 18 (4.5) |
| Gastric | 10 (2.5) |
| Other/unknown | 25 (6.3) |
| Metastasis at inclusion, n (%) | |
| 0 | 15 (3.8) |
| 1 | 227 (56.9) |
| ≥2 | 157 (39.3) |
| Most common sites of metastasis; n (%) | |
| Liver | 332 (83.2) |
| Lymph nodes | 86 (21.6) |
| Peritoneum | 55 (13.8) |
| Lung | 28 (7.0) |
| Previous lines; n (%) | |
| 1 | 217 (54.4) |
| 2 | 92 (23.1) |
| ≥2 | 90 (22.6) |
| Type of previous lines, n (%) | |
| SSA | 342 (85.7) |
| PRRT | 109 (27.3) |
| TKI | 108 (27.1) |
| Chemotherapy | 80 (20.1) |
| Clinical trial | 42 (10.5) |
| TACE or locoregional therapy | 11 (2.8) |
| Immunotherapy | 7 (1.8) |
| Others | 6 (1.5) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; PRRT, peptide receptor radionuclides; SSA, somatostatin analogs; TKIs, tyrosine kinase inhibitors; WHO, World Health Organization.
| Characteristic . | Total (N = 399) . |
|---|---|
| Median age (range); years | 62 (22–83) |
| Sex; n (%) | |
| Male | 228 (57.1) |
| Female | 171 (42.9) |
| Race; n (%) | |
| Caucasian | 380 (95.2) |
| Hispanic | 13 (3.3) |
| African | 6 (1.5) |
| ECOG-PS; n (%) | |
| Score 0 | 213 (53.4) |
| Score 1 | 125 (31.3) |
| Score ≥ 2 | 20 (5) |
| Unknown | 41 (10) |
| Tumor grade WHO; n (%)a | |
| Grade 1 | 147 (36.8) |
| Grade 2 | 197 (49.4) |
| Grade 3 | 50 (12.5) |
| Unknown | 5 (1.3) |
| Differentiation; n (%) | |
| NET | 361 (90.5) |
| NEC | 28 (7) |
| Unknown | 10 (2.5) |
| Functionality; n (%) | |
| Yes | 98 (24.6) |
| No | 295 (73.9) |
| Unknown | 6 (1.5) |
| Primary tumor location, n (%) | |
| Small intestine | 177 (44.4) |
| Pancreas | 167 (41.9) |
| Colorectal | 18 (4.5) |
| Gastric | 10 (2.5) |
| Other/unknown | 25 (6.3) |
| Metastasis at inclusion, n (%) | |
| 0 | 15 (3.8) |
| 1 | 227 (56.9) |
| ≥2 | 157 (39.3) |
| Most common sites of metastasis; n (%) | |
| Liver | 332 (83.2) |
| Lymph nodes | 86 (21.6) |
| Peritoneum | 55 (13.8) |
| Lung | 28 (7.0) |
| Previous lines; n (%) | |
| 1 | 217 (54.4) |
| 2 | 92 (23.1) |
| ≥2 | 90 (22.6) |
| Type of previous lines, n (%) | |
| SSA | 342 (85.7) |
| PRRT | 109 (27.3) |
| TKI | 108 (27.1) |
| Chemotherapy | 80 (20.1) |
| Clinical trial | 42 (10.5) |
| TACE or locoregional therapy | 11 (2.8) |
| Immunotherapy | 7 (1.8) |
| Others | 6 (1.5) |
| Characteristic . | Total (N = 399) . |
|---|---|
| Median age (range); years | 62 (22–83) |
| Sex; n (%) | |
| Male | 228 (57.1) |
| Female | 171 (42.9) |
| Race; n (%) | |
| Caucasian | 380 (95.2) |
| Hispanic | 13 (3.3) |
| African | 6 (1.5) |
| ECOG-PS; n (%) | |
| Score 0 | 213 (53.4) |
| Score 1 | 125 (31.3) |
| Score ≥ 2 | 20 (5) |
| Unknown | 41 (10) |
| Tumor grade WHO; n (%)a | |
| Grade 1 | 147 (36.8) |
| Grade 2 | 197 (49.4) |
| Grade 3 | 50 (12.5) |
| Unknown | 5 (1.3) |
| Differentiation; n (%) | |
| NET | 361 (90.5) |
| NEC | 28 (7) |
| Unknown | 10 (2.5) |
| Functionality; n (%) | |
| Yes | 98 (24.6) |
| No | 295 (73.9) |
| Unknown | 6 (1.5) |
| Primary tumor location, n (%) | |
| Small intestine | 177 (44.4) |
| Pancreas | 167 (41.9) |
| Colorectal | 18 (4.5) |
| Gastric | 10 (2.5) |
| Other/unknown | 25 (6.3) |
| Metastasis at inclusion, n (%) | |
| 0 | 15 (3.8) |
| 1 | 227 (56.9) |
| ≥2 | 157 (39.3) |
| Most common sites of metastasis; n (%) | |
| Liver | 332 (83.2) |
| Lymph nodes | 86 (21.6) |
| Peritoneum | 55 (13.8) |
| Lung | 28 (7.0) |
| Previous lines; n (%) | |
| 1 | 217 (54.4) |
| 2 | 92 (23.1) |
| ≥2 | 90 (22.6) |
| Type of previous lines, n (%) | |
| SSA | 342 (85.7) |
| PRRT | 109 (27.3) |
| TKI | 108 (27.1) |
| Chemotherapy | 80 (20.1) |
| Clinical trial | 42 (10.5) |
| TACE or locoregional therapy | 11 (2.8) |
| Immunotherapy | 7 (1.8) |
| Others | 6 (1.5) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; NEC, neuroendocrine carcinoma; NET, neuroendocrine tumor; PRRT, peptide receptor radionuclides; SSA, somatostatin analogs; TKIs, tyrosine kinase inhibitors; WHO, World Health Organization.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
